<h4>Background</h4>Thrombopoietin receptor agonists combined with anti-thymocyte globulin (ATG) and cyclosporine (CsA) are the standard immunosuppressive therapy (IST) for severe/very severe aplastic anemia (SAA/VSAA). This evidence concerns the gene MPL and idiopathic aplastic anemia.